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Adult hippocampal neurogenesis is a physiological mechanism contributing to
hippocampal memory formation. Several studies associated altered hippocampal
neurogenesis with aging and Alzheimer’s disease (AD). However, whether amyloid-β
protein (Aβ)/tau accumulation impairs adult hippocampal neurogenesis and,
consequently, the hippocampal circuitry, involved in memory formation, or altered
neurogenesis is an epiphenomenon of AD neuropathology contributing negligibly to
the AD phenotype, is, especially in humans, still debated. The detrimental effects of
Aβ/tau on synaptic function and neuronal viability have been clearly addressed both in
in vitro and in vivo experimental models. Until some years ago, studies carried out on
in vitro models investigating the action of Aβ/tau on proliferation and differentiation of
hippocampal neural stem cells led to contrasting results, mainly due to discrepancies
arising from different experimental conditions (e.g., different cellular/animal models,
different Aβ and/or tau isoforms, concentrations, and/or aggregation profiles). To date,
studies investigating in situ adult hippocampal neurogenesis indicate severe impairment
in most of transgenic AD mice; this impairment precedes by several months cognitive
dysfunction. Using experimental tools, which only became available in the last few
years, research in humans indicated that hippocampal neurogenesis is altered in
cognitive declined individuals affected by either mild cognitive impairment or AD as
well as in normal cognitive elderly with a significant inverse relationship between the
number of newly formed neurons and cognitive impairment. However, despite that such
information is available, the question whether impaired neurogenesis contributes to AD
pathogenesis or is a mere consequence of Aβ/pTau accumulation is not definitively
answered. Herein, we attempted to shed light on this complex and very intriguing topic
by reviewing relevant literature on impairment of adult neurogenesis in mouse models of
AD and in AD patients analyzing the temporal relationship between the occurrence of
altered neurogenesis and the appearance of AD hallmarks and cognitive dysfunctions.
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HIPPOCAMPAL NEUROGENESIS AND
MEMORY
The hippocampus is recognized as a brain area primarily involved
in memory formation, e.g., pattern separation, emotional
memory, and cognitive flexibility (Lazarov and Hollands, 2016;
Anacker and Hen, 2017; Hainmueller and Bartos, 2020). The
hippocampal circuitry consists of a unidirectional, trisynaptic
excitatory pathway in which the dentate gyrus (DG) of the
hippocampus receives inputs from the entorhinal cortex (EC),
which are then delivered to the CA3 area of the hippocampus and
from there to CA1. In turn, CA1 projects to the subiculum and
hippocampal outputs are sent back to the deep layers of EC. The
classical experimental paradigm used to investigate hippocampal
plasticity, underlying memory formation, is the long-term
potentiation (LTP) at the CA3-CA1 synapse not involving the
DG (Malenka and Nicoll, 1999), and the EC-DG-CA3-CA1 axis
could be strongly affected if this pathway is corrupted at the
DG. In fact, DG supports various mnemonic functions including
contextual discrimination, pattern separation, novelty detection,
and integration of individual episodes into a framework of
experiences (Hainmueller and Bartos, 2020). Interestingly, the
subgranular zone (SGZ) of the DG in the hippocampus is
known to be one of the two neurogenic niches in the adult
brain, the other being the subventricular zone of the lateral
ventricles (Gage, 2019). Adult neurogenesis occurring at the SGZ
allows integration of newly formed neurons in the DG circuits
(Kitabatake et al., 2007), thus providing this brain area with
marked plasticity. As such, adult hippocampal neurogenesis at
the DG has been proposed to strongly participate in formation of
hippocampal-dependent memory (Gonçalves et al., 2016; Toda
et al., 2019; Hainmueller and Bartos, 2020).
Additionally, the hippocampus is one of the brain areas
primarily affected by aging and Alzheimer’s disease (AD) (Selkoe,
2011). Alzheimer’s disease is themost common cause of dementia
in the elderly and is characterized by memory loss and cognitive
dysfunction. The majority of AD cases are sporadic, and the
remaining cases are associated with genetic factors [i.e., familial
AD (FAD)]. Mutations in genes, encoding either the amyloid
precursor protein (APP) or enzymes catalyzing its proteolytic
cleavage (presenilin 1 and 2—PSEN1 and 2—subunits of
γ-secretase responsible for amyloid-β peptide—Aβ–generation),
along with microtubule-associated protein tau (MAPT) encoding
the tau protein, are responsible for FAD. Nowadays, it is widely
recognized that memory failure in AD is due to synaptic
alterations caused by intra- and extracellular accumulation
of Aβ and hyperphosphorylated tau oligomers (Crews et al.,
2010; Puzzo et al., 2017). Experimental evidence also suggests
that early alterations of DG neurogenesis may concur to the
pathogenesis of this neurological disorder (Mu and Gage, 2011;
Unger et al., 2016).
AD AND NEUROGENESIS: IN VITRO
STUDIES
In the last 15 years, many studies investigated
hippocampal neurogenesis [i.e., proliferation and
neuronal differentiation of hippocampal neural stem
cells (NSCs)] in in vitro and in vivo experimental
AD models.
In vitro experimental paradigms usually consisted of
NSC incubation with Aβ. However, researches carried out
in various laboratories led to contrasting results about the
effects of proliferation/differentiation of hippocampal NSCs,
mainly because of different (i) Aβ preparations (monomeric,
oligomeric, or fibrillar); (ii) peptide lengths (40 vs. 42 amino
acids); and (iii) working concentrations, which are often
irrelevant from a physiological point of view. For example,
in 2004 López-Toledano and Shelanski reported that in
vitro treatment of hippocampal NSCs with micromolar
concentrations of Aβ42 oligomers dose-dependently increased
their neuronal differentiation (López-Toledano and Shelanski,
2004). Conversely, more recent results obtained either with
lower Aβ concentrations or in cultured NSCs isolated from
mouse models harboring the most common genetic alterations
observed in FAD indicated impaired proliferation and reduced
neuronal differentiation of hippocampus-residing NSCs. In
particular, Lee et al. (2013) found that exposure of human
NSCs to Aβ-containing conditioned medium from SK-N-
MC cells expressing APP Swedish mutation reduced NSC
proliferation, impaired neurogenesis, and promoted gliogenesis
via glycogen synthase kinase 3β (GSK-3β) activation. Moreover,
the exposure of human neural stem cell line hNS1 to nanomolar
concentrations of Aβ42 significantly promoted cell proliferation
and glial cell specification by increasing the pool of proliferating
glial precursors without affecting neuronal differentiation
(Bernabeu-Zornoza et al., 2019). A recent study from our lab
demonstrated that treatment of cultured murine hippocampal
NSCs with Aβ42 oligomers (200 nM)—able to cross plasma
membrane, to accumulate intracellularly, and to induce GSK-3
activation (Ripoli et al., 2013, 2014, Scala et al., 2015)—negatively
affected their proliferation and neuronal differentiation (Li Puma
et al., 2019). Similar results were obtained in NSCs infected with
HSV-1, which triggered APP phosphorylation and cleavage with
consequent accumulation of several APP fragments including
Aβ in several cell types (De Chiara et al., 2010; Piacentini et al.,
2011, 2015). The HSV-1-induced hyperproduction of Aβ was
correlated with the antimicrobic activity of Aβ42 and interpreted
as a defensive response of the infected cell (Soscia et al., 2010;
Kumar et al., 2016). Strategies aimed at limiting the production
and accumulation of Aβ inside cells (as the use of a γ-secretase
inhibitor or the 4G8 antibody raised against Aβ oligomers able to
be intracellularly uploaded; Tampellini et al., 2007) counteracted
the effects of Aβ42 on in vitro neurogenesis (Li Puma et al.,
2019). Altered proliferation and neuronal differentiation were
also observed in NSCs isolated from 3× Tg-AD mouse embryos
(Leone et al., 2019). These cells exhibited high levels of Aβ
oligomers compared with NSCs isolated from wild-type (WT)
mouse. Emerging evidence also suggests that downregulated
expression of the nucleoporin Nup153 negatively affects the
neurogenic niche of 3 × Tg AD mice. Accordingly, restoration
of Nup153 levels in hippocampal 3 × Tg-AD NSCs promoted
their proliferation, migration, and neuronal maturation
(Leone et al., 2019).
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HIPPOCAMPAL NEUROGENESIS IN FAD
MOUSE MODELS
More robust results have been obtained from studies performed
in in vivo FAD mouse models often exhibiting impaired
neurogenesis correlated with accumulation of molecular AD
hallmarks (e.g., Taniuchi et al., 2007; Hollands et al., 2016, 2017;
Baglietto-Vargas et al., 2017). However, depending on the FAD
model used, this impairment may rely on reduced neurogenesis
(lower NSC proliferation, decreased neuronal differentiation,
and/or reduced survival of newly formed neurons) or increased
gliogenesis (normal of even increased NSC proliferation,
followed by differentiation toward the glial rather than neuronal
phenotype). Nevertheless, despite the consensus about altered
neurogenesis in these mouse models, a clear understanding
of whether and how much this impairment contributes to
memory/cognitive dysfunction in AD is still missing.
Various FAD mouse models have been developed resembling
peculiar features of the disease, which are based on one or
more gene-coding mutations in proteins critically involved in
AD (Unger et al., 2016). The most applied models use Tg2576
mice (Hsiao, 1998), which overexpress APP harboring the
Swedish double mutation—KM670/671NL; PDAPPmice (Games
et al., 1995), which overexpress APP harboring the Indiana
(V717F) mutation; and J20 mice (Mucke et al., 2000), which
overexpress APP harboring both Swedish and Indianamutations.
Other models associate APP mutations to other mutations
accounting for PSEN1 and 2 genes encoding for presenilin 1
and 2, as for example the double transgenic “APP Swedish
PS11E9” (APPswe/PS11E9) mouse model (Jankowsky et al.,
2001) or APP/PS1 mice harboring APP Swedish and London
(V717I) along with the PS1 M146L mutation (Baglietto-Vargas
et al., 2017). Finally, the 5 × FAD mouse model, which is a
more complex model harboring all five AD-linked mutations
accounting for Aβ formation, has also been developed (Oakley
et al., 2006). All these models do not consider familial mutations
involving the tau protein, which is the other key protein in
AD. In this regard, a mouse model representative of the full
AD pathology has been developed, associating mutation in the
MAPT gene, encoding for tau protein, with those of the other
key proteins in AD (APP and PS1). This 3 × Tg-AD model
contains three mutations associated with FAD: APP Swedish,
PSEN1 M146V, and MAPT P301L (Oddo et al., 2003).
What about neurogenesis in these FAD mouse models?
Demars et al. (2010) reported a drastic reduction of NSC
proliferation [identified through 5′-bromo-deoxyuridine
(BrdU) incorporation] in the SGZ of the hippocampus of
APPswe/PS11E9 mice, at 2 months of age, with respect to
the age-matched WT animals. These alterations, taking place
before the formation of amyloid deposits, were followed by
a significant reduction in the number of cells acquiring a
neuronal (doublecortin+ -DCX) phenotype (i.e., BrdU+/DCX+
cells) with respect to age-matched WT mice. In agreement
with Demars’s results, in the same experimental model Unger
et al. (2016) found a reduced number of BrdU-positive cells
evaluated at 3 months of age, 30 days after BrdU injection,
but an increased numbers of PCNA+ cells. PCNA is a protein
expressed by proliferating cells in the late G1 and S phases of
mitosis, and this difference, observed with these two methods
of analysis, may suggest alteration in the cell cycle. However,
most of these new cells (positive for either BrdU or PCNA)
did not survive during maturation resulting in a reduced
number of BrdU+/DCX+ and PCNA+/DCX+ cells, thus
indicating impaired adult hippocampal neurogenesis. Similar
findings were also obtained in Tg2576 mice, which showed
increased NSC proliferation in the SGZ of the hippocampus
DG but reduced integration of newly formed neurons in the
DG at an age at which these mice exhibited neither amyloid
extracellular deposits nor major cognitive impairment (Unger
et al., 2016). Unger’s data in Tg2576 mice were in agreement
with those obtained by Krezymon et al. (2013) in the same
mouse model. In APP/PS1 mice, Baglietto-Vargas et al. found
a reduced number of SGZ precursor cells along with reduced
numbers of BrdU+/DCX+ cells at 4–6 months, i.e., slightly
before the onset of cognitive dysfunction (Baglietto-Vargas et al.,
2017). Also, 5 × FAD mice exhibited an early impairment of
neurogenesis with significantly reduced DCX+ cells in the DG
starting from 2 months of age (Moon et al., 2014). In 2008,
Rodrìguez et al. demonstrated impaired neurogenesis in terms
of NSC proliferation and neuronal differentiation/integration of
the DG even in 3 × Tg-AD mice. In this mouse, a significant
reduction of neurogenesis was evident in females at 4 months
of age with respect to age-matched controls, while male mice
exhibited these alterations later. Findings about early alteration
of hippocampal neurogenesis in 3 × Tg-AD mice were also
confirmed by Hamilton et al. (2010). Interestingly, Zheng et al.
(2017) demonstrated that intrahippocampal injection of Aβ42
in ovariectomized mice inhibited neurogenesis, which were
recovered by 17β-estradiol (E2) treatment; this finding further
supported the impact of estrogens in regulating neurogenesis
and their potential role in AD pathogenesis. Of note, several
conflicting results have been reported on the J20 mouse model,
which was found to exhibit either increased neurogenesis
with increasing age (López-Toledano and Shelanski, 2007) or
impaired neurogenesis independently on Aβ (Pan et al., 2016)
and additionally on the APP/PS1mice, which exhibited increased
neurogenesis at later age (Yu et al., 2009), thus indicating that
effects on neurogenesis may also depend on a combination
of mutations.
A detailed description of how neurogenesis is altered in
different AD mouse models was reviewed by Chuang (2010) and
Wirths (2017). In Table 1, we summarized how neurogenesis
is altered in various AD models, highlighting the age at which
neurogenesis was impaired and the age at which cognitive
dysfunction started.
The finding that impairment of hippocampal neurogenesis
in FAD mice occurs before (i) AD hallmarks accumulation and
(ii) appearance of learning and memory dysfunction suggests
that the former might have a causal role in cognitive decline
characterizing prodromal AD.
In support of this hypothesis, experimental evidence indicates
that ablation of hippocampal neurogenesis in APPswe/PS11E9
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TABLE 1 | Alteration of adult hippocampal neurogenesis in FAD and sporadic AD mouse models.








APP Swe PS1 1E9
(FAD)
Reduced proliferation of NSCs (BrdU+).
Reduced survival of newly generated
cells. Reduced neuronal commitment
(DCX+)
2 months 8 months Demars et al., 2010
Increased number of PCNA+ and
PCNA+/DCX+ NSCs. Reduced number
of BrdU+ NSCs 30 days after BrdU
injection. Reduced number of newly
generated cells neurons
(BrdU+/NeuN+)
3 months Unger et al., 2016
Tg2576 (FAD) Increased proliferation of NSCs
(PCNA+) and of newly generated
neuroblasts (PCNA+/DCX+ cells).
Reduced survival of newly generated
cells. Reduced number of newly
generated cells neurons
(BrdU+/NeuN+)
3 months 6–8 months Unger et al., 2016
APP/PS1 (FAD) Reduced proliferation of NSCs (BLPL+).
Reduced number of BrdU+/DCX+ cells
4–6 months 6 months Baglietto-Vargas et al.,
2017
Increased proliferation of NSCs
(BrdU+); increased number of newly
generated neuroblasts (BrdU+/DCX+)
and mature neurons (BrdU+/NeuN)
9 months 9 months Yu et al., 2009
5xFAD (FAD) Decrease of neuroblasts (DCX+) in the
DG
2 months 4–5 months Moon et al., 2014




6 months Rodríguez et al., 2008
J20 (FAD) Increased proliferation and neuronal
differentiation




Reduced proliferation of NSCs (BrdU+)
along with reduced neuronal
commitment (DCX+)
5 months 10 months De Chiara et al., 2019; Li
Puma et al., 2019
mice alters hippocampal circuitry and excitability exacerbating
performance deficits with respect to age-matched non-ablated
animals (Hollands et al., 2017). Similar results were also observed
in 5 × FAD mice, exhibiting worsened cognitive abilities after
ablation of adult hippocampal neurogenesis (Choi et al., 2018).
On the contrary, stimulation of neurogenesis with drugs (P7C3),
Wnt3-expressing lentivirus, or physical exercise ameliorates
cognitive deficits in transgenic 5 × FAD mice and reduces
amyloid burden (Choi et al., 2018). These authors suggested
that neither exercise nor stimulation of adult hippocampal
neurogenesis alone had beneficial effects but only the association
of the two stimuli was effective in this AD mouse model. In
slight contrast with this study, physical exercise was sufficient
to reduce Aβ plaque burden in 3 × Tg-AD mice, to increase
neurogenesis at the DG, and to improve cognitive functions
(Kim et al., 2019). Moreover, the experimental paradigm of
“enriched environment” was effective in ameliorating cognitive
functions in APPswe/PS11E9 mice along with rescue of neural
progenitor cell proliferation in the hippocampus, survival and
incorporation of newly born cells in preexisting hippocampal
circuits, and reduction of Aβ load and tau phosphorylation
in the hippocampus of this FAD model (Lazarov et al., 2005;
Hu et al., 2010). In any case, all these studies highlighted
a positive correlation between hippocampal neurogenesis and
cognitive functions in AD experimental models, even if it
is known that physical exercise does not selectively improve
neurogenesis but it acts on several targets (e.g., BDNF and other
factors; Saraulli et al., 2017; Liu and Nusslock, 2018), which
may support cognitive functions independently on neurogenesis.
Finally, Yan et al. (2014) showed that adult bone marrow-derived
mesenchymal stem cell transplantation improves memory and
cognitive functions of APP/PS1 mice by enhancing endogenous
neurogenesis in hippocampal SGZ. Another recent study (Micci
et al., 2019) demonstrated that exosomes (containing miR-322,
miR-17, and miR-485 miRNAs acting at the synaptic level),
released from NSCs, significantly decrease Aβ oligomer binding
at synapses and protect the hippocampus from Aβ oligomer-
induced impairment of LTP and memory deficits. Therefore,
NSCs might significantly contribute to fight the progression
of the disease, independently on the replacement of lost
neurons. Conversely, a partial rescue of the impairment of adult
hippocampal neurogenesis was observed following reductions
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of Aβ load in double transgenic APP/PS1 mice by passive Aβ
immunotherapy (Biscaro et al., 2009).
Notably, all these studies demonstrated that stimuli
ameliorating/increasing neurogenesis reduce the appearance
of AD hallmarks; this suggests the possibility that not only
Aβ/pTau affect neurogenesis, but also molecular mechanisms
controlling neurogenesis influence Aβ clearance/degradation
and/or tau phosphorylation.
Even if aging does not represent a pathological condition, it
is a main risk factor for AD and aged people and experimental
models often exhibit a decline of cognitive abilities. Dentate
gyrus is one of the primary initial targets of normal aging
(reviewed in Lazarov and Hollands, 2016), and hippocampal
neurogenesis is negatively affected by this process, resulting
in reduced NSC proliferation rates, neuroblast numbers, and
immature neurons as well as differentiated granule cells in the
DG (Lazarov and Hollands, 2016; Toda et al., 2019). These aging-
dependent effects on neurogenesis could impact on structural
and functional plasticity of the hippocampus, likely contributing
to cognitive deficits in the elderly. Indeed, strategies aimed to
increase adult neurogenesis in the hippocampus of aged mice
[e.g., by transient overexpression of a negative regulator of
dendritic spines, Kruppel-like factor 9 (McAvoy et al., 2016) or by
attenuating bone morphogenetic protein signaling (Yousef et al.,
2015)] improved their cognitive abilities and long-term memory
(Toda et al., 2019). Notably, the above-cited FAD models also
showed an age-dependent decrease in neurogenesis associated
with an increase in the number of Aβ-containing neurons in the
hippocampus and the presence of Aβ plaques.
HIPPOCAMPAL NEUROGENESIS IN
HSV-1-INFECTED MOUSE MODEL
All the mouse models discussed above are genetically modified
to develop AD hallmarks/pathology. This does not resemble
what occurs in sporadic AD, in which a “normal” subject
not carrying familial AD mutations starts exhibiting signs of
impaired memory and learning because of undefined triggering
factors. From this point of view, data obtained in a mouse
model of HSV-1 infection and the recurrent reactivation that we
recently set up are worth mentioning (De Chiara et al., 2019).
This mouse model is reminiscent of sporadic AD phenotype.
In fact, after infection and multiple cycles of virus reactivation
promoting its spreading within the brain, the infected mice
exhibited accumulation of amyloid-β and hyperphosphorylated
tau proteins in several brain areas including the hippocampus.
These molecular changes were accompanied by memory deficits
that were very marked after 7 cycles of viral reactivation in mice
and not found in age-matchedmock-infectedmice not exhibiting
Aβ or pTau accumulation (De Chiara et al., 2019).
Infected mice also exhibited impaired adult hippocampal
neurogenesis consisting in (i) reduced proliferation of NSCs
residing in the SGZ and (ii) decreased differentiation toward the
neuronal phenotype. These changes were statistically significant
before the onset of memory deficits, i.e., after 2 cycles of thermal
stress. Specifically, in the brain of infected mice the number of
proliferating NSCs (identified through BrdU and Ki67 labeling)
in the SGZ of the DG was significantly reduced with respect
to mock-infected mice, and the percentage of cells acquiring
glial phenotype [i.e., immunoreactive for the glial fibrillary acidic
protein (GFAP)] vs. neuronal one [doublecortin (DCX)-positive]
was significantly higher than in mock-infected cells (Li Puma
et al., 2019). These findings suggested us that in this experimental
model alteration of hippocampal neurogenesis precedes memory
impairment, strongly supporting the contention that altered
neurogenesis contributes to memory deficits also in sporadic AD.
HIPPOCAMPAL NEUROGENESIS, APP,
AND APP CLEAVAGE PRODUCTS
Interestingly, mice lacking amyloid precursor protein (APP KO)
did not exhibit alterations in neurogenesis following HSV-1
infection and recurrent virus reactivations (Li Puma et al.,
2019) despite the presence of viral particles in the hippocampus.
Rather, mice lacking APP exhibited a higher number of BrdU-
positive cells in the DG (Coronel et al., 2019a; Li Puma
et al., 2019). These results suggest that virus per se does not
have direct effects on neurogenesis and that APP cleavage
products (e.g., Aβ) may play a major role in modulating adult
hippocampal neurogenesis. As extensively reviewed in Lazarov
and Demars (2012), Aβ is not the only APP product affecting
neurogenesis in the hippocampus of adult mice. Other APP
metabolites, derived from proteolytic processing by specific
secretases, such as the secreted N-terminal-soluble fragments
of APP cleaved by α- (sAPPα) or β-secretase (sAPPβ), and
the APP intracellular C-terminal domain (AICD), cleaved
by γ-secretase, reportedly modulate various NSC functions
including proliferation, neuronal vs. glial differentiation, and
death (Coronel et al., 2019b). In particular, sAPPα, obtained
by the physiological non-amyloidogenic cleavage of APP, has
neuroprotective and neurotrophic functions by promoting
proliferation of NSCs (Demars et al., 2011, 2013). In contrast,
sAPPβ derived by the Aβ-producing amyloidogenic pathway of
APP has a lower efficacy than α counterpart (Demars et al.,
2013). However, both sAPPα and sAPPβ were found to increase
proliferation of neural precursor cells derived from the SGZ of
adult rats in vitro and to promote glial differentiation (Baratchi
et al., 2012). Finally, in human embryonic teratocarcinoma cells
(NT-2/D1), often used as experimental model to investigate
neural differentiation, sAPPα promotes glial fate (Kwak et al.,
2006) by stimulating bone morphogenic protein signaling
(Kwak et al., 2014), which is involved in aged-associated
cognitive decline.
Unlike sAPPα and sAPPβ, AICD seems to negatively impact
on neurogenesis. In fact, as reviewed in Coronel et al. (2019b)
and Lazarov and Demars (2012), AICD strongly inhibited
proliferation of NSCs acting as transcriptional regulator. Indeed,
in AICD transgenic mice proliferation and survival of progenitor
cells were strongly reduced while neuronal differentiation was
unaffected (Ghosal et al., 2010). Moreover, NSC differentiation
reportedly depended on γ-secretase activity (Gadadhar et al.,
2011).
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Although HSV-1 infection in cultured hippocampal NSCs
determined increased APP processing with the consequent
intracellular accumulation of Aβ peptides and intranuclear
accumulation of AICD, we found that the 4G8 antibody
(recognizing the 17–24 sequence of Aβ) was able to completely
revert the effects of HSV-1 on in vitro neurogenesis, suggesting
that the contribution of other APP fragments (e.g., AICD) to
HSV-1-induced impaired neurogenesis is negligible. However,
we cannot exclude, in vivo, that other APP metabolites
generated after HSV-1-induced APP amyloidogenic cleavagemay
participate in the alteration of neurogenesis.
Finally, although most of the functions exerted by APP and
its proteolytic fragments have been described, the molecular
mechanisms and the signaling pathways involved in these effects
remainmostly unknown. APP belongs to a superfamily including
the homologs APLP1 and APLP2, which are expressed in
APP KO mice. While mouse KO for APP/APLP1 is viable,
APP/APLP2, and APLP1/APLP2 KO mice do not survive, which
stresses the importance of APLP2. Interestingly, the in vivo
silencing of APLP2 in an APP/APLP1 double knockout mouse
keeps cortical progenitors much longer in their undifferentiated
state, which is consistent with the view that APLP2 plays a key
role in the commitment of neuronal progenitors to neuronal
differentiation (Shariati et al., 2013).
ALZHEIMER’S DISEASE, MEMORY LOSS,
AND ALTERED NEUROGENESIS: THE
ROLE OF TAU
Although this review primarily deals with the impact of APP
fragments on neurogenesis, experimental evidence suggests that
tau is the real bad player in AD. Specifically, tau oligomers target
neurons and astrocytes involved in tripartite synapses, which
affect synaptic transmission and synaptic plasticity (Guerrero-
Muñoz et al., 2015; Fá et al., 2016; Piacentini et al., 2017;
Puzzo et al., 2017; Li et al., 2018). Tau has also been reported
to negatively affect hippocampal neurogenesis (see Fuster-
Matanzo et al., 2012). In 2010, Demars et al. demonstrated
that APPswe/PS11E9 mice exhibited a significant increase
in tau phosphorylation in several brain areas including the
hippocampus, likely contributing to the development of the
AD phenotype. As discussed above, exposure of these mice
to an enriched environment reduced, besides ameliorating
cognitive functions and neurogenesis, also accumulation of
phosphorylated tau in their hippocampus (Hu et al., 2010).
In agreement with these results, more recent studies reported
that human tau mice and FTDP-17 mutant tau mice exhibited
a decrease in proliferation of neuronal precursors (Komuro
et al., 2015; Houben et al., 2019). Pallas-Bazarra et al. (2016)
demonstrated a novel role played by tau in NSC survival after
stressful stimuli; they demonstrated that tau is fundamental for
morphological and functional maturation of newborn granule
neurons using a tau KO mouse model. Tau−/− mice show
impairment in the maturation of newborn granule neurons, and
they are insensitive to the modulation of adult hippocampal
neurogenesis exerted by external stimuli. Tau protein also
facilitates DCX-positive cell migration from the SGZ to the
granular layer of the hippocampus, a process that requires
a dynamic microtubule network. Therefore, it is conceivable
that the increased dynamics and destabilization of microtubules
caused by hyperphosphorylation of tau protein may contribute
to impaired hippocampal neurogenesis (Fuster-Matanzo et al.,
2009, 2012). Very recent studies reported that pTau accumulation
in DG interneurons impair adult hippocampal neurogenesis by
suppressing GABAergic transmission (Zheng et al., 2020) and
that tau KO mice exhibit increased neurogenesis in the DG at 14
months of age compared withWTmice matched for age (Criado-
Marrero et al., 2020). In support of a role for tau in neurogenesis,
Houben et al. (2019) demonstrated that deletion of tau in a
transgenic mouse model of tauopathy (Tg30 mice harboring
FTDP-17 mutant tau) rescued the alteration in hippocampal
neurogenesis exhibited by these mice.
There is a strong interplay between Aβ and tau, and a
common, although controversial, opinion in the field is that
tau pathology would be triggered by Aβ (Bloom, 2014). For
example, it was demonstrated that endogenously produced Aβ
induces tau hyperphosphorylation in cell cultures (Wang et al.,
2006) and recent in vivo PET-imaging studies suggested that
Aβ is a prerequisite for tau pathology (Franzmeier et al., 2019;
Pontecorvo et al., 2019). Two main protein kinases have been
shown to be involved in aberrant tau phosphorylation: the cyclin-
dependent kinase (Cdk5) and GSK-3β. A deregulation of these
kinases, induced by extracellular amyloid loading, results in
tau hyperphosphorylation (Maccioni et al., 2001). As discussed
above, tau hyperphosphorylation was found in FAD mice in
which genetic alterations account for APP and its cleaving
enzymes (APPswe/PS11E9; Demars et al., 2010), supporting the
idea of a cross talk among Aβ and tau. Reduction of Aβ burden
by scyllo-inositol in TgF344-AD rats reduced tau pathology and
rescued adult hippocampal neurogenesis (Morrone et al., 2020).
We cannot exclude that the effects of tau on adult neurogenesis
aremediated by Aβ load, although another view has been recently
proposed that Aβ and tau exert their detrimental action by acting
in parallel, probably sharing common targets, rather than acting
in series (Puzzo et al., 2020).
ALZHEIMER’S DISEASE, MEMORY LOSS,
AND ALTERED NEUROGENESIS: HUMAN
STUDIES
Despite the large number of studies about the relationship
among altered neurogenesis and AD, some questions still
remain unanswered: is this alteration disrupting the hippocampal
circuitry involved in memory formation? Does it significantly
contribute to memory loss in AD? Are the results obtained in
in vitro and in vivo murine models translatable to humans? Is
recovery/activation of neurogenesis a useful tool to prevent the
onset and/or counteract the progression of AD? Some tentative
answers to these questions can be found in recent reviews from
Kempermann et al. (2018) and Cosacak et al. (2020), but more in-
depth investigations are absolutely needed to address these issues.
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What about neurogenesis in humans and its involvement in
neurodegenerative diseases? Recently, some independent studies
(Mathews et al., 2017; Boldrini et al., 2018; Moreno-Jiménez
et al., 2019; Tobin et al., 2019) demonstrated that (i) adult
hippocampal neurogenesis also occurs in human brain and it
contributes to adding new granule cells to the DG throughout
the lifespan even though the efficiency of this mechanism
decreases with age and (ii) in AD patients, the number and
maturation of newly generated neurons progressively decline
as the disease proceeds. In particular, Tobin et al. found a
significant inverse relationship between the number of newly
formed neuroblasts and cognitive impairment, withMCI patients
exhibiting fewer DCX+/PCNA+ cells than cognitive normal
subjects (Tobin et al., 2019). Another study correlated adult
hippocampal neurogenesis with AD and major depressive
disorder, which are known to interact reciprocally elevating the
risk for one another (Berger et al., 2020). Although several
previous researches unsuccessfully attempted to identify adult
hippocampal neurogenesis in humans, and then questioned the
existence of this process in the adult brain (Paredes et al., 2018;
Sorrells et al., 2018), more recent studies demonstrated the
existence of this process owing to the application of newmethods
of tissue sample preservation from postmortem brain, thus
allowing a more precise recognition of NSCs, and additionally,
the application of this approach to AD patient brains.
CONCLUSIONS
Collectively, literature discussed in this review adds new layers of
knowledge on the link between impairment of adult hippocampal
neurogenesis and cognitive dysfunction in AD. Specifically, it
is reasonable to hypothesize that altered adult hippocampal
neurogenesis, due to intracellular accumulation of Aβ and pTau,
may have a significant impact on the hippocampal circuitry
underlying memory formation, which actively contributes to
disease progression. Indeed, data obtained from murine models
reminiscent of both FAD and sporadic AD clearly indicate
that alterations of neurogenesis (in terms of reduced NSC
proliferation, survival of neuroblasts, and functional integration
of newly formed neurons) occur before the appearance of
memory impairment and that stimuli, increasing hippocampal
neurogenesis, ameliorate cognitive functions of AD mice. To
date, a correlation between altered hippocampal neurogenesis
and AD has been suggested in humans, although the cause–
effect relationship between these two processes has not been
ascertained yet. Therefore, strategies aimed at restoring and/or
boosting adult hippocampal neurogenesis in both normal elderly
people and subjects at high risk of AD (e.g., individuals
with MCI) could emerge as effective strategies to prevent
the onset and/or counteracting the progression of the disease.
In this perspective, it is worth mentioning that in mouse
models exposed to extremely low-frequency electromagnetic
fields a significantly enhanced adult neurogenesis at both
hippocampal DG and the subventricular zone has been reported
along with memory improvement (Cuccurazzu et al., 2010;
Leone et al., 2014; Podda et al., 2014; Mastrodonato et al.,
2018).
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